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efﬁcacy of a new, cobalt chromium thin-strut, coronary absorbable polymer–coated, sirolimus-eluting
stent.
Background Bioabsorbable polymers on drug-eluting stents may lower the long-term risks of
inﬂammation, delayed healing, and adverse events.
Methods Weenrolled patients with symptomatic coronary artery diseasewith stable or unstable angina
pectoris and >50% diameter stenosis, amenable to coverage with a 23-mm long stent in a vessel 2.5
to 3.5 mm in diameter. All patients received dual antiplatelet therapy after implantation. Patients, in
groups of 10, underwent repeat angiography, intravascular ultrasound, and optical coherence
tomography at 4, 6, or 8 months, and all patients were seen or contacted at 18 months of follow-up.
Results The median (range) in-stent late lumen loss (LLL) was 0.03 mm (0.22 to 0.21 mm), 0.10 mm
(0.03 to 1.2 mm), and 0.08 mm (0.01 to 0.28 mm), at 4, 6, and 8 months, respectively. At 18 months,
the median in-stent LLL was 0.08 mm (0.30 to 0.46 mm). On optical coherence tomography, the
proportion of uncovered stent struts decreased from a median of 7.3% (range 0.4% to 46.3%) at 4
months to 0% (range: 0% to 3.4%) at 18 months. The percentage of neointimal volume obstruction by
intravascular ultrasound increased from a median of 5.3% to 9.1% between 4 and 6 months and
remained nearly unchanged thereafter through 18 months of follow-up. The only recorded major
adverse cardiac event was a myocardial infarction.
Conclusions At 18 months of follow-up, this absorbable polymer–coated, cobalt chromium sirolimus-
eluting stent was associated with a low and stable in-stent LLL, complete strut coverage, and no stent
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Abbreviations
and Acronyms
AP = absorbable polymer(s)
APSES = absorbable polymer-
coated, sirolimus-eluting
stent(s)
BMS = bare-metal stent(s)
CI = conﬁdence interval
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
ISA = incomplete stent
apposition
IVUS = intravascular
ultrasound
LLL = late lumen loss
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
MLD = minimal lumen
diameter
OCT = optical coherence
tomography
QCA = quantitative coronary
angiography
SES = sirolimus-eluting stent
ST = stent thrombosis
TLR = target lesion
revascularization
TVR = target vessel
revascularization
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1027Compared with bare-metal stents (BMS), drug-eluting
stents (DES) are associated with markedly lower restenosis
rates after percutaneous coronary interventions (1–3).
However, the polymer coating that elutes the antiproliferative
drug has been linked to complications including delayed
vessel healing, hypersensitivity reactions, neoatheroma, and
restenosis, with the potential for repeat intervention, stent
thrombosis (ST), acute myocardial infarction (MI), and
sudden death (4–6). The potential link between the perma-
nent polymer and late adverse events has prompted the
development of biodegradable sources of drug delivery to
a stented vessel. Several next-generation designs emerged
recently, including DES with reservoirs containing the drug
and a variety of biodegradable polymer coatings (7–10).
Absorption of the polymer may lower the rates of ST,
particularly beyond 1 year after stent implantation. In addi-
tion, stents with absorbable polymers (APs) may allow
a shorter duration of dual antiplatelet therapy (DAPT) than
currently recommended (11,12).
The MiStent Sirolimus Eluting Absorbable Polymer
Coronary Stent System, or MiStent (Micell Technologies,
Durham, North Carolina) sirolimus-eluting stent (SES),
was developed using a cobalt-chromium stent with very thin,
64-mm struts coated with crystalline sirolimus in a fully AP
(Fig. 1). Compared with existing DES, the unique
combination of crystalline sirolimus and AP enables the
deposition of drug into the surrounding tissue and its pro-
longed elution at a controlled rate, providing therapeutic
tissue concentrations of sirolimus through 6 months post-
implantation, without an initial burst of drug release. The
coating is cleared from the stent in 45 to 60 days and
absorbed into the tissue within 90 days, leaving an inert
BMS, as conﬁrmed during pre-clinical animal testing (13).
This approach of drug delivery to the artery is aimed at
achieving tissue coverage of the stent struts without excessive
neointimal proliferation.
The primary objectives of the DESSOLVE (DES With
Sirolimus and a Bioabsorbable Polymer for the Treatment
of Patients With De Novo Lesion in the Native Coronary
Arteries) study, the ﬁrst-in-human study, were to provide
a preliminary evaluation of the safety and efﬁcacy of the
MiStent APSES for percutaneous coronary intervention in
the treatment of patients with symptomatic ischemic heart
disease and to provide guidance for future randomized
trial designs. We report here the angiographic, intravas-
cular ultrasound (IVUS), and optical coherence tomog-
raphy (OCT) imaging studies in patients at 4, 6, 8, andTechnologies, Volcano, Johnson & Johnson, St. Jude Medical, and Abbott Vascular; and
research/grant support from Abbott Vascular, Boston Scientiﬁc, Medtronic Cardiovas-
cular, Elixir, and Stentys. Dr. Donohoe is a consultant for Micell Technologies. Dr.
Kandzari has received consulting/educational honoraria fromBostonScientiﬁc, Medtronic
Cardiovascular, and Micell Technologies; and research/grant support from Abbott
Vascular, Boston Scientiﬁc, and Medtronic Cardiovascular. Dr. Wijns has received
grants and consulting fees/honoraria from Micell Technologies, Abbott Vascular,18 months, as well as clinical outcomes through 18
months of follow-up. The planned total duration of
follow-up is 5 years.
Patient Population and Methods
Enrollment. This prospective, nonrandomized, multicenter
study was approved by the ethics committees of the
participating medical centers, and all patients provided
written informed consent to participate. They were enrolled
between November 2010 and March 2011 at 5 centers in
New Zealand, Belgium, and
Australia (Online Appendix A).
Patients presented stable or
unstable angina pectoris or overt
or silent myocardial ischemia and
were candidates for treatment of
a single de novo type A, B1, or
B2 coronary lesion, according to
the American College of Cardi-
ology/American Heart Associa-
tion classiﬁcation (14). The study
lesion was >50% in diameter in
a reference vessel 2.5 to 3.5 mm
in diameter and amenable to
coverage with a 23-mm long
stent. One additional lesion in
a nontarget vessel could be
treated before the study proce-
dure; however, this was not
considered part of the study. The
inclusion/exclusion criteria are
listed in Online Appendix B.
Schedule of follow-up visits and
diagnostic investigations. Each
patient underwent a baseline
medical evaluation, and APSES
implantation was performed
using standard percutaneous
procedures. After pre-dilation of
the lesion, the stent was advanced
to the lesion site and expanded
using a semicompliant balloon.
Baseline angiographic and IVUS data were collected
according to the instructions of the respective core labora-
tories. After the procedure, creatine kinase–myocardial band
fraction were measured 8 and 24 h after the index procedure.AstraZeneca, Biotronik, Boston Scientiﬁc, Cardio3Biosciences, Cordis, Medtranic,
Orbus Neich, St. Jude Medical, Terumo, Therabel, and Tryton Medical. All other
authors have reported that they have no relationships relevant to the contents of this
paper to disclose.
Manuscript received March 12, 2013; revised manuscript received May 3, 2013,
accepted May 9, 2013.
Figure 1. MiStent Sirolimus-Eluting Absorbable Polymer Stent
The design of the MiStent (Micell Technologies, Durham, North Carolina), constructed from cobalt chromium, is zigzag hoops that are largely in-phase with offset
crowns linked by 3 S-shaped connectors per hoop. The connectors at both ends are straight and link crowns.
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1028All patients received DAPT according to local practice, with
a 12-month duration recommended.
All patients were contacted 30 days after the procedure.
At 4 months, the ﬁrst subgroup of 10 patients enrolled in
the trial underwent repeat angiography, IVUS, and initial
OCT of the target vessel (15,16). A second subgroup of
10 patients returned for the same diagnostic procedures at
6 months, and a third subgroup of 10 patients returned at
8 months. All patients had clinical assessments at 8 and
12 months and planned repeat angiography, IVUS, and
OCT at 18 months (Fig. 1). All imaging studies were
analyzed by independent core laboratories (Online
Appendix A).
Study endpoints. PRIMARY. The primary endpoint of the
study was angiographic in-stent late lumen loss (LLL),
deﬁned as the difference between the post-procedural
minimal lumen diameter (MLD) in the stented segment and
the MLD in the same segment at follow-up measured by the
angiography core laboratory (Yale University, New Haven,
Connecticut). The LLL was ascertained in the 3 subgroups
of 10 patients at 4, 6, and 8 months and in 27 patients at 18
months of follow-up.
SECONDARY. The procedural secondary endpoints included
device success, deﬁned as a <50% ﬁnal in-stent residual
diameter stenosis by quantitative coronary angiography
(QCA), using the MiStent SES device; lesion success,
deﬁned as a <50% ﬁnal in-stent residual diameter stenosis
by QCA using any percutaneous method; and procedural
success, deﬁned as a <50% ﬁnal in-stent residual diameter
stenosis by QCA using the assigned and any other device
without cardiac death, MI, or repeat target lesion revascu-
larization (TLR) before discharge from the hospital.
The invasive secondary endpoints, evaluated at 4, 6, 8,
and 18 months of follow-up using QCA and the IVUS(Stanford University, Stanford, California) and OCT (Case
Western, Cleveland, Ohio) core laboratories, included in-
lesion LLL, percentage of diameter stenosis, MLD, and
binary restenosis of the treated lesion. OCT was used to
estimate the extent of strut coverage and volume of plaque and
detect the presence of dissections, aneurysms, incomplete
stent apposition (ISA), or thrombus. The heterogeneity of
neointimal hyperplasia over time was tested by the measure-
ment of a coefﬁcient of variation. IVUS was used to assess
the volume of hyperplasia and plaque, the presence and extent
of ISA, and possible dissections and aneurysm formation
and to measure the cross-sectional areas of stents and lumens.
The clinical secondary endpoints included major adverse
cardiac events (MACE), deﬁned as all deaths, Q- and non–
Q-wave MI, and target vessel revascularization (TVR); rates
of overall and target vessel Q-wave MI and non–Q-wave
MI; rates of clinically driven TLR, TVR, and target vessel
failure; and rates of ST, adjudicated according to the
Academic Research Consortium deﬁnitions (17).
Device description. The stent platform is laser cut from
a thin cobalt chromium alloy tube and electro-polished. The
design of the stent is zigzag hoops with each hoop linked to
the next by 3 connectors in the body of the stent. These links
are “S” shaped and connect offset peaks (18). At each end
the connectors are straight and short and link crowns. The
stent is coated with antiproliferative crystalline sirolimus
within a fully AP and mounted on a stent delivery system.
The stent coating consists of poly lactide-co-glycolic acid,
a biocompatible and biodegradable polymer used in many
medical devices (19), combined with crystalline sirolimus.
The drug and polymer coating deposited onto the stent is
approximately 5 mm thick on the luminal side and 15 mm
thick on the abluminal side. The coating process uses
a proprietary method based on supercritical ﬂuid technology
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1029(13). The dose of sirolimus is 9 to 11 mg/mm and similar to
that of the CYPHER SES (Cordis Corporation, Miami
Lakes, Florida). Study stents were 15 or 23 mm in length
and 2.5, 3.0, or 3.5 mm in diameter, on a rapid-exchange
balloon delivery system.
Study monitoring and management. All investigational sites
and data were monitored to ensure compliance with the
protocol and verify that the data matched the source medical
records. A clinical events committee adjudicated the study
endpoints and pre-deﬁned events that occurred throughout
the study and a data and safety monitoring board reviewed
all safety issues with regard to the ongoing study.
Statistical analyses. The analyses are limited to descriptive
statistics and presented as count and percentage forFigure 2. Sequence of the DESSOLVE I Study, From Initial Enrollment of 30 Patie
Coronary angiography and intravascular ultrasound (IVUS) were performed at the tim
coherence tomography (OCT) was performed, at 4, 6, or 8 months and at 18 months
and 18 months of follow-up, which has been planned to continue at yearly intervals
the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries.categorical variables, mean  SD and 95% conﬁdence
interval (CI), or median (range) for continuous variables.
SAS version 9.1.3 SP2 (SAS Institute, Cary, North Caro-
lina) was used for the analyses.Results
Clinical and imaging compliance. Clinical information on 30
patients was collected through 18 months, corresponding to
a 100% clinical compliance. Follow-up imaging studies were
performed at 18 months in all but 3 patients; serious
noncardiac diseases had developed in 2 patients and 1
patient declined to undergo the procedure. The 18-monthnts to 18-Month Follow-up
e of study enrollment; angiography and IVUS were repeated, and optical
of follow-up. All patients also underwent clinical evaluations at 30 days and 12
up to 5 years. DESSOLVE ¼ DES With Sirolimus and a Bioabsorbable Polymer for
Table 2. Baseline Angiographic Characteristics
Target vessel
Right coronary artery 12 (40) (23–59)
Left anterior descending coronary artery 11 (37) (20–56)
Left circumﬂex coronary artery 7 (23) (10–42)
Reference vessel diameter, mm 2.9  0.3 (2.7–3.0)
Lesion length, mm
Mean 13.2  3.8 (11.7–14.6)
<10 8 (27) (12–46)
10–19 21 (70) (51–85)
20 1 (3) (0.1–17)
Minimum luminal diameter, mm 0.9  0.2 (0.8–1.0)
Percentage of diameter stenosis 69  8 (66–72)
TIMI ﬂow
2 2 (7) (1–22)
3 28 (93) (78–99)
Complex characteristics
45 bend 5 (17) (6–35)
Eccentric lesion 3 (10) (2–27)
Calciﬁcation
Moderate 7 (23) (10–42)
Severe 1 (3) (0.1–17)
American Heart Association lesion class
A 6 (20) (8–39)
B1 13 (43) (26–63)
B2 7 (23) (10–42)
C 4 (13) (4–31)
Values are n (%) of observations (95% CI) or mean  SD (95% CI).
CI ¼ conﬁdence interval; TIMI ¼ Thrombolysis In Myocardial Infarction.
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1030imaging analyses are, therefore, limited to 27 patients
(Fig. 2).
Characteristics of the study sample. The mean  SD age of
the overall study sample was 62.6  9.95 years, 22 (73%)
were men, 26 (87%) were hypercholesterolemic, and 7 (23%)
were diabetic. Other important baseline characteristics of
the 30 patients are shown in Table 1. The baseline angio-
graphic characteristics are shown in Table 2. The lesion
length was 13.2  3.8 mm and the mean MLD was 0.9 
0.2 mm. In two-thirds of patients, the target lesion was
classiﬁed as B1 or B2, according to the American Heart
Association classiﬁcation.
Procedural outcomes. Each patient underwent treatment of
a single target lesion. The APSES was implanted using
a semicompliant balloon with a maximum stent deployment
pressure of 13.9  2.7 atm and post-dilation occurred in
76.7% of patients. The post-procedure in-stent MLD was
2.8  0.3 mm (95% CI: 2.7 to 2.9 mm) and residual
percentage of diameter stenosis was 2.3  7.4% (95%
CI: 0.5% to 5.0%). The lesion, device, and procedural
successes were 100%, 96.7%, and 100%, respectively. In 1
patient, a ﬁrst MiStent SES that had failed to cross
a markedly calciﬁed stenosis was removed, before the
successful implantation of a second stent. Nonstudy stents
were successfully implanted in 7 nontarget lesions before
treatment of the target vessel.
Long-term angiographic results. The averaged QCA
measurements made at 4, 6, and 8 months of follow-up in
each subgroup of 10 patients and at 18 months in 27 patients
are shown in Table 3. Compared with the immediate
2.8  0.3-mm post-procedure in-stent MLD, the in-stentTable 1. Baseline Characteristics of 30 Patients Enrolled in the
DESSOLVE I Study
Age, yrs 62.6 (44–86)
Men 22 (73)
History of:
Myocardial infarction 5 (17)
Percutaneous coronary intervention 12 (40)
On nontarget vessel 9 (30)
On target vessel 3 (10)
Coronary risk factors
Hypercholesterolemia 26 (87)
Past or current smoking 23 (77)
Hypertension 23 (77)
Diabetes 7 (23)
Indications for index procedure
Angina
Stable 21 (70)
Unstable 6 (20)
Silent ischemia 3 (10)
Values are mean (range) or n (%) of observations.
DESSOLVE ¼ DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients
With De Novo Lesion in the Native Coronary Arteries.MLD (95% CI) in all 30 patients, up to 8 months, was
2.7  0.4 mm (95% CI: 2.6 to 2.9 mm), corresponding to
a mean  SD in-stent LLL of 0.1  0.2 mm (95% CI: 0.04
to 0.5 mm). In each subgroup of 10 patients, the median
(range) in-stent LLL was 0.03 mm (0.22 to 0.21 mm), 0.1
mm (0.03 to 1.20 mm), and 0.08 mm (0.01 to 0.28 mm)
at 4, 6, and 8 months, respectively. The median (range) 4-,
6- and 8-month in-stent and in-lesion percentage of
diameter stenosis was 5.4% (12.8% to 46.6%) and 11.6%
(0.2% to 46.6%), respectively. The 18-month cumulative
in-stent and in-lesion binary restenosis rates were both 0%.
IVUS studies. At the immediate post-procedural IVUS
examinations, performed in 27 patients, edge dissection and
ISA were observed in 1 (4%) and 4 (15%) patients,
respectively. Of 4 post-procedural ISAs, 3 resolved by the
follow-up visit and 1 persisted. Acquired ISAs were detected
in 2 patients, resolved by 18 months of follow-up in 1
patient. No increase in vessel volume index >20% (positive
remodeling) was observed.
An increase in neointimal obstruction was observed up to
8 months of follow-up, followed by no further progression
up to 18 months, and the peristent plaque volume had
returned to baseline level at 18 months. These IVUS
observations were consistent with signiﬁcant neointimal
suppression and a favorable peristent arterial response at
Table 3. Results of Follow-up Quantitative Coronary Angiography at 4, 6, and 8 Months Each in 10 Patients
and at 18 Months in 27 Patients
Months
4
(n ¼ 10)
6
(n ¼ 10)
8
(n ¼ 10)
18
(n ¼ 27)
Reference vessel diameter, mm 2.8 (2.0 to 3.4) 2.9 (2.6 to 3.7) 2.9 (2.6 to 3.2) 2.9 (2.1 to 3.7)
Minimum luminal diameter, mm
In-stent 2.7 (1.8 to 3.0) 2.9 (1.4 to 3.3) 2.8 (2.4 to 3.1) 2.7 (1.7 to 3.4)
In-lesion 2.5 (1.8 to 2.7) 2.5 (1.4 to 3.0) 2.6 (1.7 to 2.9) 2.5 (1.6 to 3.4)
Percentage of diameter stenosis
In-stent 5.6 (8.4 to 17.2) 3.1 (12.8 to 46.6) 6.9 (4.3 to 13.8) 6.1 (11.4 to 17.0)
In-lesion 12.0 (1.2 to 27.0) 12.6 (0.2 to 46.6) 10.5 (7.2 to 41.8) 16.2 (4.7 to 42.3)
Late loss, mm
In-stent 0.03 (0.22 to 0.21) 0.10 (0.03 to 1.2) 0.08 (0.01 to 0.28) 0.08 (0.30 to 0.46)
In-lesion 0.06 (0.15 to 0.19) 0.02 (0.21 to 1.19) 0.02 (0.17 to 0.59) 0.04 (0.43 to 0.70)
Binary restenosis 0 0 0 0
Values are median (range).
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103118 months, without late in-stent neointimal “catch-up”
phenomenon. The values for each subgroup of patients
at 4, 6, and 8 months and in 25 analyzable patients at
18 months are shown in Figure 3.
Optical coherence tomography. The OCT measurements
are summarized in Table 4. The proportion of uncovered
stent struts decreased from a median of 7% (range 0.4%
to 46%) at 4 months, to 3% (range 0% to 35%) at 6 months,
4% (range 0% to 8%) at 8 months, and 0% (range 0% to 3%)Figure 3. Percentage of Neointimal Obstruction on Serial Intravascular
Ultrasound Examinations at 4 (n ¼ 8), 6 (n ¼ 5), and 8 (n ¼ 7) Months
of Follow-Up
Note the minimal increase in neointimal obstruction between the averaged 4-,
6-, and 8-month (n ¼ 20) and the 18-month (n ¼ 20) measurements.at 18 months. The median percentages of stent struts mal-
apposition at 4, 6, 8, and 18 months were 0.4% (range 0% to
23%), 0.7% (range 0% to 19%), 0.3% (range 0% to 2%), and
0% (range 0% to 1%), respectively. The neointimal tissue
volume increased from a median of 6 mm3 (range 2 to 17
mm3) to 15 mm3 (range 5 to 33 mm3) between 4 and 6
months of follow-up and remained numerically similar
between 6 and 18 months of follow-up.
Antithrombotic therapy. At the time of discharge from the
hospital, all patients were on a DAPT regimen, including
aspirin and either clopidogrel, ticlopidine, or prasugrel, and
73% continued on DAPT for 12 months. This decrease in
DAPT duration was associated with no thrombotic event.
Clinical events up to 18 months of follow-up. No patient
died or experienced TLR, TVR, or ST during the 18
months of this study. One patient had a non–Q-wave MI at
44 days after the index procedure as determined by increased
levels of troponin after a diagnostic angiogram. The cumu-
lative 18-month MACE rate was 3.3%.Discussion
This ﬁrst-in-human study was designed to examine the
temporal patterns of tissue healing and the proof-of-concept
for restoration to a BMS. We chose 4 months post stent
deployment as the ﬁrst assessment point because the poly-
mer coating is completely absorbed atw3 months. Repeated
imaging at 6, 8, and 18 months allowed a detailed assess-
ment of the tissue strut coverage, strut malapposition,
positive remodeling, and other changes that have been
associated with some of the durable polymer DES.
Our study conﬁrmed, up to 18 months, the preliminary
safety and efﬁcacy of the cobalt chromium thin-strut
MiStent SES, from which a poly lactide-co-glycolic acid
Table 4. Optical Coherence Tomography Analysis in Each Subgroup of 10 Patients and in 27 Patients
Who Underwent Interventional Imaging at 18 Months
Months
4
(n ¼ 10)
6
(n ¼ 9)
8
(n ¼ 9)
18
(n ¼ 27)
% of uncovered stent struts 7.3 (0.4–46.3) 2.9 (0–35) 3.8 (0–8.5) 0 (0–3.4)
% of malapposed stent struts 0.4 (0–22.7) 0.7 (0–18.9) 0.3 (0–1.6) 0 (0–1.3)
Stent volume, mm3 105 (51–196) 146 (66–272) 136 (83–268) 132 (57–284)
Lumen volume, mm3 103 (45–187) 131 (60–268) 134 (64–204) 114 (36–211)
Neointimal volume, mm3 6.0 (2.3–17.5) 14.6 (4.8–33.0) 18.1 (8.2–64.0) 16.4 (6.4–73.2)
% net volume obstruction 7.0 (2.3–22.9) 10.0 (5.6–18.8) 13.3 (6.0–23.9) 16.4 (6.1–47.8)
Neointimal thickness (hyperplasia), mm 2.6 (0.6–24.6) 96.5 (39.3–143.6) 144.5 (74.8–236.2) 132.4 (68.1–343.2)
Values are median (range).
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1032polymer coating is absorbed in 45 to 60 days. Crystalline
sirolimus is delivered locally in sustained, therapeutic
concentrations up to 6 months, without initial burst. The
small angiographic in-stent LLL at each time point, along
with the low neointimal volume obstruction on IVUS,
indicates stent efﬁcacy. Of particular interest, and in contrast
to many other SESs, there was no evidence of late “catch-
up”; the angiographic LLL, neointimal volume on IVUS,
and neointimal thickness on OCT were all stable between
the early and 18-month follow-up.
ST after 1 year post-implantation has been a major
concern for ﬁrst-generation DES, with randomized trials
and real-world registry data suggesting an unremitting
incidence of w0.6% per year (6,20). Currently, ST is the
most feared long-term complication of DES implantation
(10,21,22), as it commonly leads to MI or death (23). ST
has been correlated with incomplete endothelialization and
underexpansion of the stent (24). In addition, the durable
polymer coating of ﬁrst-generation DES has been identi-
ﬁed as a factor associated with ST, especially beyond 1 year
(4,21–23). The second-generation DES, with thinner
struts and thinner, more biocompatible polymers, are asso-
ciated with a suppression of the neointimal response and
a more rapid re-endothelialization (25). Randomized trials
and large registries of second-generation DES in selected
patient populations have generally conﬁrmed their non-
inferiority or superiority compared with ﬁrst-generation
DES (26–28). A recent meta-analysis of studies of current-
generation DES found a lower rate of ST at 2 years after
implantation of the second-generation ﬂuropolymer-coated,
everolimus-eluting stent than after the deployment of
a BMS or other DES (29,30).
Although ST is less frequent in the ﬁrst 1 to 2 years after
DES implantation, later adverse events do remain a concern.
The 5-year follow-up of the SIRTAX late randomized
comparison of SESs versus paclitaxel-eluting stents with
permanent polymer found a continuous increase in angio-
graphic LLL, and a 2% to 3% annual increase in MACErate beyond the ﬁrst year (31). The Japanese Cypher registry
of nearly 13,000 patients reported an ongoing 0.26% annual
rate of ST and 2.2% rate of TLR, without a decrease over
time (32). Late MACE, including TLR, occur after the
implantation of other permanent polymer DES designs
(33,34), although the incidence of restenosis is lower with
newer than with older DES (31).
Multiple factors may contribute to the incidence of
MACE late after stent implantation. Ongoing inﬂammation
is present in arteries stented with permanent polymeric DES
and may contribute to neoatheroma, late “catch-up,” and ST
(35). Neoatheroma occurs earlier and is more common after
DES implantation, although it continues to occur with
BMS (36,37). The incidence of late adverse events is likely
to be lower after the absorption of the polymer, such as from
the MiStent SES, than after the implantation of the DES
coated with a permanent polymer, as there is less ongoing
inﬂammation than with permanent polymers. In a meta-
analysis of randomized trials, metal DES that release an
antiproliferative drug from an absorbable polymer coating
had lower rates of TLR and ST, out to 4 years, than metal
stents that released a drug from a durable polymer (10). It
was hypothesized that the inﬂammatory response, a major
contributor to the processes that cause late adverse events, is
attenuated after the absorption of the polymeric coating
compared with a persistent polymer. Thus, biodegradable
polymers have the potential to lower the rate of long-term
adverse events attributed to durable polymers.
Although second-generation DES compared with ﬁrst-
generation DES have decreased the risk of ST, there is
a need to develop devices that lower that risk further as well
as the reliance on DAPT after percutaneous coronary
interventions. Despite the design of better DES and more
“biocompatible” materials in the past decade, a risk of
inﬂammation persists with all permanent polymers. DES
coated with bioabsorbable polymers remain effective, while
eliminating the risks of ST and decreasing the need for
prolonged DAPT.
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1033The association between permanent polymers and adverse
vascular reactions has been clearly demonstrated. The
randomized LEADERS (Limus Eluted from A Durable
versus ERodable Stent) trial studies showed that a biolimus-
eluting stent coated with a biodegradable polymer had a
lower risk of adverse cardiac events associated with very late
ST through 5 years of follow-up, improving the long-term
clinical outcomes compared with SESs coated with a durable
polymer (38). However, 1 study, the SORT OUT (Scan-
dinavian Organization for Randomized Trials with Clinical
Outcome) V trial, suggests that at 1 year of follow-up, there
may be no additional clinical beneﬁt between a biodegrad-
able polymer biolimus-eluting stent and a ﬁrst-generation
durable polymer SES (39). However, long-term follow-up is
still pending. Whereas the new generation of DES might be
coated with various types of bioabsorbable polymer, with
different times to complete absorption, most likely will confer
the same vascular and clinical beneﬁts by eliminating the
permanent polymer-driven mechanisms leading to ST (40).
Study limitations. This is a small, nonrandomized,
hypothesis-generating, ﬁrst-in-human study. The anti-
proliferative efﬁcacy and, in particular, the safety of the stent
require conﬁrmation in a larger randomized trial, which has
already commenced.
Conclusions
This ﬁrst-in-human study of the MiStent SES in simple
coronary artery lesions revealed a >95% median strut co-
verage on OCT performed at 6 and 8 months of follow-
up and, up to 18 months after device implantation, a small
and minimally progressive in-stent LLL and no stent-
related MACE. These results suggest that the MiStent is at
least as effective as the durable polymer-based SES, or
newer generation bioabsorbable polymer and bioabsorbable
stent platforms. The apparent stability of intimal hyper-
plasia and the absence of late “catch-up” phenomenon
warrant further randomized trials of this stent in larger
sample populations.
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